Lipid profile, statin treatment and treatment goal attainment in adults with FH in UK primary care (n=3064)
| Characteristics | Unit | Baseline | 12 months | 24 months |
| Individuals’ lipid profile | ||||
| Total cholesterol (mmol/L) | Mean (SD) | 7.76 (1.42) | 5.56 (1.40) | 5.42 (1.30) |
| LDL-cholesterol (mmol/L) | Mean (SD) | 5.42 (1.41) | 3.45 (1.37) | 3.28 (1.23) |
| HDL-cholesterol (mmol/L) | Mean (SD) | 1.50 (0.49) | 1.49 (0.47) | 1.51 (0.49) |
| Triglycerides (mmol/L) | Median (IQR) | 1.70 (1.20–2.47) | 1.40 (1.00–2.00) | 1.32 (0.93–2.00) |
| Potency of prescribed statins* | ||||
| (n=3064) | (n=2142) | (n=1940) | ||
| Low | n (%) | 264 (8.62) | 142 (6.63) | 111 (5.72) |
| Medium | 2145 (70.01) | 1225 (57.19) | 1067 (55.00) | |
| High | 655 (21.38) | 775 (36.18) | 762 (39.28) | |
| LDL-C reduction at follow-up | ||||
| FH treatment goal attainment | (n=3064) | (n=1662) | ||
| Attained ≥50% reduction | n (%) | 895 (29.21) | 558 (33.57) | |
| Non-attainment of 50% reduction | 2169 (70.79) | 1104 (66.43) | ||
| General population goal attainment | (n=3064) | (n=1662) | ||
| Attained ≥40% reduction | n (%) | 1566 (51.11) | 935 (56.26) | |
| Non-attainment of 40% reduction | 1498 (48.89) | 727 (43.74) |
*Statin potency at 12 months and 24 months was reported in individuals with LDL-C records at baseline and 12 months, as well as statin potency records at 12 and 24 months, respectively. Total number and percentage n (%) for potency were based only on those with potency records, with the exclusion of missing records.
FH, familial hypercholesterolaemia; HDL, high-density lipoprotein; LDL, low-density lipoprotein.